European Commission Approves Nivolumab for Previously Treated, Locally Advanced, Unresectable or Metastatic Urothelial Cancer

June 8, 2017 – On June 2, the European Commission (EC) approved nivolumab for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. This makes nivolumab the first immuno-oncology agent approved in the European Union for the treatment of patients with this common type of bladder cancer. “Bladder cancer has an estimated 151,000 new cases diagnosed annually … (leggi tutto)